Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 9/20 | 0.58 |
| ▸ | CTSL | P07711 | 2/20 | 0.58 |
| ▸ | CTSB | P07858 | 1/20 | 0.58 |
| ▸ | CTSS | P25774 | 1/20 | 0.58 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.54 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.49 |
| ▸ | REN | P00797 | 2/20 | 0.44 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.44 |
| ▸ | MAP1LC3A | Q9H492 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28774928 | 1.00 | CTSK (0.58) | CTSKCTSLCTSBCTSSCAPN1 | |
| SCHEMBL7159331 | 0.87 | CTSK (0.65) | CTSKCTSLCTSBCTSSCAPN1 | |
| SCHEMBL25293909 | 0.87 | CTSK (0.65) | CTSKCTSLCTSBCTSSCAPN1 | |
| SCHEMBL5557615 | 0.87 | CTSK (0.65) | CTSKCTSLCTSBCTSSCAPN1 | |
| SCHEMBL25286879 | 0.84 | CTSK (0.66) | CTSKCTSLCTSBCTSSCAPN1 | |
| SCHEMBL2180828 | 0.81 | CTSK (0.58) | CTSKCTSLCTSBCTSSCAPN1 | |
| SCHEMBL2180830 | 0.81 | CTSK (0.58) | CTSKCTSLCTSBCTSSCAPN1 | |
| SCHEMBL245261 | 0.81 | CTSK (0.68) | CTSKCTSLCTSBCTSSCAPN1 | |
| SCHEMBL7666744 | 0.80 | CTSK (0.63) | CTSKCTSLCTSBCTSSCAPN1 | |
| SCHEMBL7391820 | 0.80 | CTSK (0.63) | CTSKCTSLCTSBCTSSCAPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070014721-A1 | Hydrazide conjugates as imaging agents | LANTHEUS MEDICAL IMAGING, INC. | 2007-01-18 | — | — | US | disclosed |
| US-20070014721-A1 | Hydrazide conjugates as imaging agents | LANTHEUS MEDICAL IMAGING, INC. | 2007-01-18 | — | — | US | disclosed |
| US-20070014721-A1 | Hydrazide conjugates as imaging agents | LANTHEUS MEDICAL IMAGING, INC. | 2007-01-18 | — | — | US | disclosed |
| WO-2007005491-A1 | HYDRAZIDE CONJUGATES AS IMAGING AGENTS | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070014721-A1 | Hydrazide conjugates as imaging agents | CA14, CA13, CA1 | CTSK 1070/4885CTSL 2354/4885CTSB 817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.